Correlation analysis showed that TGF-β1 (Fig. 6D , P = 0.0004, r = − 0.5119), TGF-β2 (Fig. 6E, P = 0.0022, r = − 0.4494), and TGF-β3 (Fig. 6F, P = 0.0006, r = -0.4944) were significantly negatively associated with the corresponding immunotherapy PFS of EGFR-mutated NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.